Fish Oil Intake and Seizure Control in Children with Medically Resistant Epilepsy

Diala Mohamed Ali Reda1, Nesrin Kamal Abd-El-Fatah1, Tarek El-Sayed Ismail Omar2

  • 1Department of Nutrition, Faculty of Medicine, High Institution of Public Health, Alexandria University, Alexandria, Egypt.

Insights

Fish oil supplementation, rich in Omega-3 polyunsaturated fatty acids, significantly reduced seizure frequency in children with drug-resistant epilepsy. This suggests a potential therapeutic role for Omega-3s in epilepsy management.

Area of Science:

  • Neurology
  • Nutritional Neuroscience

Background:

  • Omega-3 polyunsaturated fatty acids (PUFAs) show promise for epilepsy treatment.
  • Medically resistant epilepsy poses significant challenges in pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy of fish oil (Omega-3 PUFAs) in reducing seizure frequency and severity.
  • To assess the impact of Omega-3 supplementation in children with refractory epilepsy.

Main Methods:

  • A case-control study involving 70 children with medically resistant epilepsy.
  • Participants were divided into two groups: 35 receiving fish oil and 35 receiving a placebo.
  • Seizure frequency and severity were assessed at baseline and over three months.

Main Results:

  • 57.1% of children receiving fish oil experienced zero epileptic attacks by month three, compared to minimal improvement in the placebo group.
  • A significant difference in seizure reduction was observed between the fish oil and placebo groups.
  • No significant difference was found in seizure severity improvement between groups.

Conclusions:

  • Omega-3 polyunsaturated fatty acids can elevate the seizure threshold in epileptic patients.
  • Fish oil supplementation may be a beneficial adjunctive therapy for achieving seizure control in epilepsy.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
973
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.6K